Additive in vivo growth-inhibitory effects of flutamide and finasteride on androgen-sensitive Shionogi 115 carcinoma

Endocrine-Related Cancer

Volumn 3, Issue 3, 1996, Pages 217-227

  Chen, C ^a   Li, X ^a   Singh, S ^a   Belanger A ^a   Labrie, F ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; FINASTERIDE; FLUTAMIDE; STEROID 5ALPHA REDUCTASE INHIBITOR;

ANIMAL MODEL; ARTICLE; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER MODEL; CANCER SIZE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; MALE; MOUSE; NONHUMAN; ORCHIECTOMY; PROSTATE CANCER; TREATMENT OUTCOME;

EID: 0029993822     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0030217     Document Type: Article

References (49)

1. Anderson KM & Liao S 1968 Selective retention of dihydrotestosterone by prostatic nuclei. Nature 219 277-279.
2. Andersson S, Bishop RW & Russell DW 1989 Expression cloning and regulation of steroid 5α-reductase, an enzyme essential for male sexual differentiation. Journal of Biological Chemistry 264 16249-16255.
3. Andersson S, Bergman DM, Jenkins EP & Russel DW 1991 Deletion of steroid 5α-reductase 2 gene in male pseudohermaphroditism. Nature 354 159-161.
4. 3H]methyltrienolone (R1881) in rat prostate and human benign prostatic hypertrophy (BPH). Steroids 28 449-459.
5. Begin D, Luthy IA & Labrie F 1988 Adrenal precursor C19 steroids are potent stimulators of growth of androgen- sensitive mouse mammary carcinoma Shionogi cells in vitro. Molecular and Cellular Endocrinology 58 213-219.
6. Bélanger A, Caron S & Picard V 1980 Simultaneous radioimmunoassay of progestins, androgens and estrogens in adult rat testis. Journal of Steroid Biochemistry 13 185-190.
7. Bélanger A, Brochu M & Cliche J 1986 Levels of plasma steroid glucuronides in intact and castrated men with prostatic cancer. Journal of Clinical Endocrinology and Metabolism 62 812-815.
8. Bélanger B, Bélanger A, Labrie F, Dupont A, Cusan L & Monfette G 1989 Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: unique importance of extratesticular androgens in men. Journal of Steroid Biochemistry 32 695-698.
9. Bélanger A, Couture J, Caron S & Roy R 1990 Determination of non-conjugated and conjugated steroid level in plasma and prostate after separation of C-18 columns. Annals of the New York Academy of Sciences 595 251-259.
10. Bélanger A, Candas B, Dupont A, Cusan L, Diamond P, Gomez JL & Labrie F 1994 Changes in serum concentrations of conjugated and unconjugated steroids in 40- to 80-year-old men. Journal of Clinical Endocrinology and Metabolism 79 1086-1090.
11. Bradford M 1976 A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 72 248-254.
12. Brochu M & Bélanger A 1987 Increase in plasma steroid glucuronide levels in men from infancy to adulthood. Journal of Clinical Endocrinology and Metabolism 64 1283-1287.
13. Brochu M, Bélanger A, Dupont A, Cusan L & Labrie F 1987 Effects of Flutamide and aminoglutethimide on plasma 5α-reduced steroid glucuronide concentrations in castrated patients with cancer of the prostate. Journal of Steroid Biochemistry 28 619-622.
14. Brooks JR, Baptista EM, Berman C, Ham EA, Hichens M, Johnson DB, Primka RL, Rasmusson OH, Reynolds OF, Schmiff SM & Arth GE 1981 Response of rat ventral prostate to a new and novel 5α-reductase inhibitor. Endocrinology 109 830-836.
15. Brooks JR, Berman C, Nguyen H, Prahalada S, Primka RL, Rasmusson GH & Slater EE 1991 Effect of castration, DES, Flutamide and the 5α-reductase inhibitor, MK- 906, on the growth of the Dunning rat prostatic carcinoma, R-3327. Prostate 18 215-227.
16. Crawford D, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein DA, Davis MA & Goodman PJ 1989 A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. New England Journal of Medicine 321 419-424.
17. Denis L, Carneiro de Moura JL, Bono A, Sylvester R, Wheeton R, Newling D & Pauno MD 1993 Goserelin acetate and flutamide vs bilateral orchiectomy: a phase III EORTC trial (30853). Urology 42 119-129.
18. Desmond WJ Jr, Wolbers S J & Sato G 1976 Cloned mouse mammary cell lines requiring androgens for growth in culture. Cell 8 79-86.
19. Geller J, Albert JD, Nachtsheom DA & Loza DC 1984 Comparison of prostatic cancer tissue dihydrotestosterone levels at the time of relapse following orchiectomy or estrogen therapy. Journal of Urology 132 693-696.
20. Huggins C & Hodges CV 1941 Studies of prostatic cancer. I. Effect of castration, estrogen and androgen injections on serum phosphatases in metastatic carcinoma of the prostate. Cancer Research 1 293-307.
21. Janknegt RA, Abbou CC, Bartoletti R, Bernstein-Hahn L, Bracken B, Brisset JM, Silva FCd, Knonagel H & Venner P 1993 Orchiectomy and Anandron (Nilutamide) or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. Journal of Urology 149 77-83.
22. Kerr JF, Wyllie AH & Currie AR 1972 Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. British Journal of Cancer 26 239-257.
23. Kramer CY 1956 Extension of multiple range tests to group means with unique numbers of replications. Biometrics 12307-310.
24. Labrie F 1991 Intracrinology. Molecular and Cellular Endocrinology 78 C113-C118.
25. Labrie F 1993 Mechanism of action and pure antiandrogenic properties of flutamide. Cancer 72 3816-3827.
26. Labrie F 1995 Endocrine therapy of prostate cancer optimal form and timing. Journal of Clinical Endocrinology and Metabolism 801066-1071.
27. Labrie F & Veilleux R 1986 A wide range of sensitivities to androgens develops in cloned Shionogi mouse mammary tumor cells. Prostate 8 293-300.
28. Labrie F & Veilleux R 1988 Maintenance of androgen responsiveness by glucocorticoids in Shionogi mammary carcinoma cells in culture. Journal of the National Cancer Institute 80 966-970.
29. Labrie F, Bélanger A, Cusan L, Séguin C, Pelletier G, Kelly PA, Reeves JJ, Lefebvre FA, Lemay A & Ranaud JP 1980 Antifertility effects of LHRH agonists in the male. Journal of Andrology 1 209-228.
30. Labrie F, Dupont A, Bélanger A, Cusan L, Lacourcière Y, Monfette G, Laberge JO, Emond J, Fazekas ATA, Raynaud JP & Husson JM 1982 New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clinical and Investigative Medicine 5 267-275.
31. Labrie F, Dupont A & Bélanger A 1985 Complete androgen blockade for the treatment of prostate cancer. In Important Advances in Oncology, pp 193-217. Eds VT de Vita, S Hellman & SA Rosenberg. Philadelphia: JB Lippincott.
32. Labrie C, Bélanger A & Labrie F 1988a Androgenic activity of dehydroepiandrosterone and androstenedione in the rat ventral prostate. Endocrinology 123 1412-1417.
33. Labrie F, Veilleux R & Fournier A 1988b Low androgen levels induce the development of androgen- hypersensitive cells clones in Shionogi mouse mammary carcinoma cells in culture. Journal of the National Cancer Institute 80 1138-1147.
34. Labrie C, Trudel C, Li S, Martel C, Couet J & Labrie F 1991 Combination of an antiandrogen and a 5α- reductase inhibitor: A further step towards total androgen blockade? Endocrinology 129 566-568.
35. Labrie F, Sugimoto Y, Luu-The V, Simard J, Lachance Y, Bachvarov D, Leblanc G, Durocher F & Paquet N 1992 Structure of human type II 5α-reductase. Endocrinology 131 1571-1573.
36. Labrie F, Bélanger A, Dupont A, Luu-The V, Simard J & Labrie C 1993a Science behind total androgen blockade: from gene to combination therapy. Clinical and Investigative Medicine 16 475-492.
37. Labrie F, Dupont A, Cusan L, Gomez JL, Diamond P, Koutsilieris M, Suburu R, Fradet Y, Lemay M, Têtu B, Emond J & Candas B 1993b Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial. Clinical and Investigative Medicine 16 511-521.
38. Labrie F, Cusan L, Gomez JL, Diamond P, Suburu R, Lemay M, Tetu B, Fradet Y & Candas B 1994 Down- staging of early stage prostate cancer before radical prostatectomy: the first randomized trial of neoadjuvant combination therapy with Flutamide and a luteinizing hormone-releasing hormone agonist. Urology 44 29-37.
39. Labrie F, Cusan L, Gomez JL, Diamond P & Candas B 1995 Combination of screening and preoperative endocrine therapy: the potential for an important decrease in prostate cancer mortality. Journal of Clinical Endocrinology and Metabolism 80 2002-2013.
40. Marchetti B & Labrie F 1988 Characteristics of Flutamide action on prostatic and testicular functions in the rat. Journal of Steroid Biochemistry 29 691-698.
41. Martel C, Trudel C, Couet J, Labrie C, Bélanger A & Labrie F 1993 Blöckade of androstenedione-induced stimulation of androgen-sensitive parameters in the rat prostate by combination of Flutamide and 4-MA. Molecular and Cellular Endocrinology 91 43-49.
42. Minesita T & Yamaguchi K 1965 An androgen-dependent mouse mammary tumor. Cancer Research 25 1168- 1175.
43. Moghissi E, Ablan F & Horton R 1984 Origin of plasma androstanediol glucuronide in men. Journal of Clinical Endocrinology and Metabolism 59 417-421.
44. Orentreich N, Brind JL, Rizer RL & Vogelman JH 1984 Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. Journal of Clinical Endocrinology and Metabolism 59 551-555.
45. Plante M, Lapointe S & Labrie F 1988 Stimulatory effect of synthetic progestins currently used for the treatment of prostate cancer on growth of the androgen-sensitive Shionogi tumor in mice. Journal of Steroid Biochemistry 31 61-64.
46. Simard J, Luthy I, Guay J, Bélanger A & Labrie F 1986 Characteristics of interaction of the antiandrogen Flutamide with the androgen receptor in various target tissues. Molecular and Cellular Endocrinology 44 261- 270.
47. Thériault C & Labrie F 1991 Multiple steroid metabolic pathways in ZR-75-I human breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology 38 155- 164.
48. Vaux DL, Haecker G & Strasser A 1994 An evolutionary perspective on apoptosis. Cell 76 777-779.
49. Wingo PA, Tong T & Bolden S 1995 Cancer statistics 1995. CA Cancer Journal for Clinicians 45 8-30.